Immunogenicity and Tolerance of BNT162b2 mRNA Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Patients.

ABSTRACT:

Background

Allogeneic hematopoietic stem cell transplantation (ASCT) induces acquired immunodeficiency, potentially altering vaccine response. Herein, we aimed to explore the clinical tolerance and the humoral and cellular immune responses following anti-SARS-CoV-2 vaccination in ASCT recipients.

Methods

A prospective, non-randomized, controlled study that involved 43 ASCT subjects and 31 healthy controls. Humoral response was investigated using the Elecsys^® test anti-SARS-CoV-2. Cellular response was assessed using the QFN^® SARS-CoV-2 test. The lymphocyte cytokine profile was tested using the LEGENDplex™ HU Th Cytokine Panel Kit (12-plex).

Results

Adverse effects (AE) were observed in 69% of patients, encompassing pain at the injection site, fev

SUBMITTER: Ben Khlil AA 

PROVIDER: S-EPMC10892348 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature